

Statement of Need

Scientific advances in the field of breast cancer have led to the diagnosis of cancer at earlier stages and the development of superior treatment strategies. These improvements have translated to better survival rates for patients with breast cancer and, as a result, the long-term side effects of breast cancer treatment have become an increasingly significant factor in patient outcomes. Chemotherapy has long been the cornerstone of adjuvant therapy for breast cancer, and cardiotoxicity is a notable side effect of several commonly-used chemotherapeutic agents, specifically anthracycline- and trastuzumab-based regimens. Although the long-term effects of cancer therapy have garnered more recent study, clear guidelines do not exist to help physicians detect and treat cardiotoxicity in patients with breast cancer. The purpose of this program is to increase participant awareness and understanding of chemotherapy-associated cardiotoxicity in breast cancer by helping physicians assess risk, implement appropriate diagnostic and monitoring strategies, and devise patient-specific treatment plans.

Target Audience

This activity is intended for cardiologists and oncologists.

Accreditation/Designation Statements

Med-IQ is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Med-IQ designates this Webcast for a maximum of 0.5 *AMA PRA Category 1 Credit*™. Physicians should only claim credit commensurate with the extent of their participation.

Privacy and Confidentiality

Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us.

For detailed information about our privacy policy, please visit: www.Med-IQ.com/privacypolicy.html.

Disclosure Policy

Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement

The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Disclosure Statements

Webcast Faculty

Sandra M. Swain, MD

Fees received for promotional/non-CME activities: Genentech, ImClone, Abraxis BioScience, Eisai Inc., Roche Laboratories Inc., Johnson & Johnson, GlaxoSmithKline, Bristol-Myers Squibb

Other: Travel to Meetings: sanofi-aventis U.S.

Michael S. Ewer, MD

Consulting fees/advisory boards: Genentech, MethylGene Inc., Roche Laboratories Inc.

Contracted research: sanofi-aventis U.S.

The activity planner, **JaNeen Dancy, PharmD**, and other employees of Med-IQ have no financial relationships to disclose.

Statement of Evidence-Based Content

Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from sanofi-aventis U.S.

Expert Discussion: Chemotherapy-Associated Cardiotoxicity in Breast Cancer

Faculty

Sandra M. Swain, MD, Program Chair
Medical Director, Washington Cancer Institute
Washington Hospital Center
Professor of Medicine
Georgetown University
Washington, DC

Michael S. Ewer, MD, MPH, JD
Special Assistant to the VP for Medical Affairs
Professor of Medicine, Cardiology
University of Texas M.D. Anderson Cancer Center
Houston, TX

Learning Objectives

- Evaluate the efficacy of cardioprotective agents used in combination with infusional anthracyclines to prevent chemotherapy-associated cardiotoxicity
- Examine data on the use of cardiac injury markers in the diagnosis of early cardiac dysfunction

Comments about today's program?

Call (toll-free) 866 858 7434

E-mail info@med-iq.com

To receive credit, participants must view the CME materials, view the activity, and complete and submit the attestation and evaluation online at www.Med-IQ.com/M5.

Click on the "Get Credit" tab to complete your attestation and evaluation forms now.

Please visit us online at www.Med-IQ.com for additional activities sponsored by Med-IQ.


Med-IQ®
Inspiring Medical Education
© 2010